^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ABL1 T315I

i
Other names: ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
Entrez ID:
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
05/16/2024
Initiation :
01/25/2021
Primary completion :
07/01/2028
Completion :
07/01/2028
ABL1 • BCR
|
ABL1 T315I
|
dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • dexamethasone • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection
Phase 1/2
Takeda
Active, not recruiting
Last update posted :
03/04/2024
Initiation :
02/24/2021
Primary completion :
12/19/2024
Completion :
01/04/2027
ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4
|
BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation
|
cytarabine • Iclusig (ponatinib) • cyclophosphamide
Phase 2
Takeda
Active, not recruiting
Last update posted :
02/06/2024
Initiation :
06/30/2015
Primary completion :
04/14/2020
Completion :
06/01/2024
ABL1 • BCR
|
BCR-ABL1 fusion • ABL1 T315I • BCR-ABL1 mutation
|
Iclusig (ponatinib)
Phase 1
Ascentage Pharma Group Inc.
Recruiting
Last update posted :
11/28/2023
Initiation :
01/09/2020
Primary completion :
01/31/2024
Completion :
01/31/2024
ABL1 • BCR
|
ABL1 T315I
|
Blincyto (blinatumomab) • Nailike (olverembatinib)
Phase 3
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
09/07/2023
Initiation :
05/25/2021
Primary completion :
06/20/2023
Completion :
07/05/2024
ABL1 • BCR
|
ABL1 T315I • BCR-ABL1 mutation
|
Scemblix (asciminib)
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
07/27/2023
Initiation :
06/29/2015
Primary completion :
06/01/2025
Completion :
06/01/2025
ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP
|
BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R
|
dasatinib • Jakafi (ruxolitinib) • dexamethasone
Phase N/A
Novartis Pharmaceuticals
Completed
Last update posted :
04/06/2023
Initiation :
12/01/2020
Primary completion :
12/23/2021
Completion :
12/23/2021
ABL1 • BCR
|
ABL1 T315I
Phase 2
Ascentage Pharma Group Inc.
Active, not recruiting
Last update posted :
04/03/2023
Initiation :
04/08/2019
Primary completion :
04/01/2024
Completion :
03/01/2025
ABL1 • BCR
|
ABL1 T315I
|
Nailike (olverembatinib)
Phase 2
Ascentage Pharma Group Inc.
Active, not recruiting
Last update posted :
04/03/2023
Initiation :
04/08/2019
Primary completion :
05/01/2024
Completion :
02/01/2025
ABL1 • BCR
|
ABL1 T315I
|
Nailike (olverembatinib)
Phase 1
Institute of Hematology & Blood Diseases Hospital
Recruiting
Last update posted :
03/02/2023
Initiation :
09/01/2022
Primary completion :
08/31/2024
Completion :
12/01/2024
ABL1 • BCR
|
BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation
|
dexamethasone • Nailike (olverembatinib) • lisaftoclax (APG-2575)
Phase N/A
Novartis Pharmaceuticals
Completed
Last update posted :
11/17/2022
Initiation :
05/03/2021
Primary completion :
10/29/2021
Completion :
10/29/2021
ABL1
|
ABL1 T315I